Suchen und filtern

Gefundene Studien

CLARINET FORTE-Trial Efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in well differentiated, metastatic or locally advanced, unresectable pancreatic or midgut neuroendocrine tumours having progressed radiologically while previously treated with lanreotide Autogel® 120 mg administered every 28 days. AIO-NET-0216/ass · Rekrutierung beendet Studie anzeigen

DURTRERAD 2 ARM RANDOMIZED PHASE II TRIAL TO ASSESS THE FEASIBILITY AND EFFICACY OF A TREATMENT WITH DURVALUMAB (MEDI4736) A PDL1-INHIBITOR PLUS TREMELIMUMAB A CTLA-4- INHIBITOR IN COMBINATION WITH RADIOTHERAPY AND A TREATMENT WITH DURVALUMAB IN COMBINATION WITH RADIOTHERAPY AS FIRST-LINE THERAPY FOR PATIENTS WITH NON-RESECTABLE LOCALLY ADVANCED HPV NEGATIVE HNSCC – A COMPARISON WITH A HISTORICAL CONTROL GROUP-

AIO-KHT-0120/ass · Studie beendet Studie anzeigen

PanaMa Randomized phase II study for evaluation of efficacy and safety of maintenance treatment with 5-FU/FA plus panitumumab vs. 5-FU/FA alone after prior induction treatment with mFOLFOX6 plus panitumumab and re-induction with mFOLFOX6 plus panitumumab in case of progression for first-line treatment of patients with metastatic colorectal cancer AIO-KRK-0212 · Rekrutierung beendet Studie anzeigen

FIRE-6 Avelumab added to FOLFIRI plus Cetuximab followed by Avelumab maintenance in patients with previously untreated RAS wild-type colorectal cancer. The phase II FIRE-6-Avelumab study AIO-KRK-0118 · Rekrutierung beendet Studie anzeigen

FIRE-4.5 Randomised study to investigate FOLFOXIRI plus Cetuximab vs. FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutated metastatic colorectal cancer AIO-KRK-0116 · Rekrutierung beendet Studie anzeigen

DETECT III Multizentrische, prospektiv randomisierte Phase III Studie zum Vergleich einer antineoplastischen Therapie allein versus einer antineoplastischen Therapie plus Lapatinib bei Patientinnen mit initial HER2-negativem metastasiertem Brustkrebs und HER2-positiven zirkulierenden Tumorzellen DETECT III · Rekrutierung beendet Studie anzeigen

RIBBIT Randomisierte, offene, zwei-armige Phase III Studie zur Untersuchung der Wirksamkeit und der Lebensqualität von Patientinnen mit metastasiertem HER2-negativem, Hormonrezeptor-positivem Brustkrebs unter Erstlinienbehandlung mit endokriner Therapie in Kombination mit Ribociclib oder Chemotherapie mit / ohne Bevacizumab AIO-MAM-0117/ass · Rekrutierung beendet Studie anzeigen

CheCUP A phase II, open-label, non-randomized, multi-center study evaluating the efficacy and safety of nivolumab plus ipilimumab in patients with cancer of unknown primary site who are relapsed after or refractory to platinum-based chemotherapy AIO-CUP-0119/ass · Studie beendet Studie anzeigen

IMMUNIB An open-label, single-arm phase II study of immunotherapy with nivolumab in combination with lenvatinib for advanced stage hepatocellular carcinoma (HCC) AIO-HEP-0218/ass · Rekrutierung beendet Studie anzeigen

IMPORTANCE Randomized phase II study of immune stimulation with Pembrolizumab and radiotherapy in second line therapy of metastatic head and neck squamous cell carcinoma AIO-KHT-0222/ass · In Rekrutierung Studie anzeigen